Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies.
Cancer Chemother Pharmacol
; 75(3): 653-5, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25637551
ABSTRACT
A significant proportion of post-menopausal, patients treated with AI reports side-effects, especially bone pain. In such patients, the difficulties to treat pain and to clearly identify its causes may lead to treatment discontinuation. Ageing is associated with physiological modifications that may impair drug pharmacokinetics (PKs). The elimination can be altered, with decreased drug clearance (CL), resulting in an increased exposure to the drug, reflected by increased AUCs. The reported increases in AI exposure being around 50 %, an intermittent dosing schedule of 1 administration every other day could result in a similar drug exposure as compared to the usual daily schedule.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dor
/
Pós-Menopausa
/
Inibidores da Aromatase
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article